




RealRate

PHARMACEUTICAL 2018

Direct CORP
Rank 99 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Direct CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Direct CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Direct CORP is the variable Assets, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 67% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	45,358
Cost of Goods Sold	0
Intangible Assets	6,399
Liabilities, Current	15,828
Liabilities, Non-Current	0
Other Assets	427
Other Compr. Net Income	2.0
Other Expenses	6,633
Other Liabilities	0
Other Net Income	-1,458
Other Revenues	49,170
Property and Equipment	929
Research and Development	31,609
Selling, General and Administrative Expense	13,165

Output Variable	Value in 1000 USD
Assets	53,113
Liabilities	15,828
Expenses	51,407
Revenues	49,170
Stockholders Equity	37,285
Net Income	-3,695
Comprehensive Net Income	-3,694
BaseVar	85,489
ECR before Limited Liability	225%
Economic Capital Ratio	319%